Suppr超能文献

鸟苷对乳腺癌细胞增殖的特异性抑制作用。

Specific inhibitory effects of guanosine on breast cancer cell proliferation.

机构信息

Division of Clinical Pharmaceutics, Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, 10281 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.

Division of Clinical Pharmaceutics, Department of Pharmaceutical Sciences, Nihon Pharmaceutical University, 10281 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan.

出版信息

Biochem Biophys Res Commun. 2023 Sep 17;673:67-72. doi: 10.1016/j.bbrc.2023.06.069. Epub 2023 Jun 21.

Abstract

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-related death. Drug therapy for breast cancer is currently selected based on the subtype classification; however, many anticancer drugs are highly cytotoxic. Since intracellular levels of GTP are elevated in many cancer cells that undergo a specific cell proliferation cycle, GTP has potential as a target for cancer therapy. The present study focused on nucleosides and nucleotides and examined intracellular GTP-dependent changes in cell proliferation rates in normal (MCF-12A) and cancer (MCF-7) breast cell lines. Decreased cell proliferation due to a reduction in intracellular GTP levels by mycophenolic acid (MPA), an inosine monophosphate dehydrogenase inhibitor, was observed in both cell lines. The inhibitory effects of MPA on cell proliferation were suppressed when it was applied in combination with Guanosine (Guo), a substrate for GTP salvage synthesis, while the single exposure to Guo suppressed the proliferation of MCF-7 cells only. Although the underlying mechanisms remain unclear, since the inhibitory effects of Guo on cell proliferation did not correlate with GTP or ATP intracellular levels or the GTP/ATP ratio, there may be another cause besides GTP metabolism. Guo inhibited the proliferation of MCF-7, a human breast cancer cell line, but not MCF-12A, a human normal breast cell line. Further studies are needed to investigate the potential of applying Guo as a target for the development of a novel cancer treatment system.

摘要

乳腺癌是最常见的癌症类型,也是癌症相关死亡的主要原因。目前,乳腺癌的药物治疗是基于亚型分类进行选择的;然而,许多抗癌药物具有高度细胞毒性。由于经历特定细胞增殖周期的许多癌细胞中的 GTP 水平升高,因此 GTP 具有作为癌症治疗靶标的潜力。本研究集中于核苷和核苷酸,并研究了正常(MCF-12A)和癌症(MCF-7)乳腺细胞系中细胞内 GTP 依赖性细胞增殖率的变化。在两种细胞系中,通过肌苷单磷酸脱氢酶抑制剂霉酚酸(MPA)降低细胞内 GTP 水平导致细胞增殖减少。当 MPA 与 Guo(GTP 补救合成的底物)联合应用时,其对细胞增殖的抑制作用被抑制,而 Guo 的单次暴露仅抑制 MCF-7 细胞的增殖。虽然潜在机制尚不清楚,但由于 Guo 对细胞增殖的抑制作用与细胞内 GTP 或 ATP 水平或 GTP/ATP 比值无关,因此除了 GTP 代谢之外,可能还有其他原因。Guo 抑制了人乳腺癌细胞系 MCF-7 的增殖,但不抑制人正常乳腺细胞系 MCF-12A 的增殖。需要进一步研究以探讨将 Guo 作为开发新型癌症治疗系统的靶标的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验